OncoUrologia  

www.oncourologia.it

–

Data presented at ESMO provide further insights and greater understanding in using Pembrolizumab ( Keytruda ) in select second-line advanced urothelial carcinoma treatment settings, and importantly, demonstrate an overall survival advantage with Pembrolizumab compared to standard chemotherapy agents Vinflunine, Docetaxel and Paclitaxel, which are common in clinical practice for the treatment of this disease.

For previously treated patients, post-Platinum failure, these findings are also encouraging as they show an overall survival benefit regardless of PD-L1 status or choice of commonly used chemotherapy.

With nearly two years follow-up, these updated phase 3 data continue to show an overall survival benefit with Pembrolizumab in patients with advanced urothelial carcinoma whose cancer has progressed after receiving previous treatment for their disease.

Currently, Merck also has the largest immuno-oncology clinical development program in bladder cancer, with 29 trials underway involving Pembrolizumab as monotherapy and in combination, including four registration-enabling studies.